Erasca, Inc. $ERAS Position Increased by Vivo Capital LLC

Vivo Capital LLC raised its position in Erasca, Inc. (NASDAQ:ERAS) by 31.0% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 12,151,480 shares of the company’s stock after purchasing an additional 2,878,052 shares during the period. Erasca comprises approximately 16.3% of Vivo Capital LLC’s portfolio, making the stock its biggest holding. Vivo Capital LLC’s holdings in Erasca were worth $196,611,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in ERAS. BNP Paribas Financial Markets raised its stake in shares of Erasca by 58.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 21,579 shares of the company’s stock worth $27,000 after buying an additional 7,923 shares during the last quarter. EP Wealth Advisors LLC acquired a new stake in Erasca in the 2nd quarter valued at about $29,000. Russell Investments Group Ltd. purchased a new position in Erasca during the 3rd quarter valued at about $31,000. EntryPoint Capital LLC acquired a new position in Erasca during the fourth quarter worth about $38,000. Finally, Stifel Financial Corp purchased a new stake in shares of Erasca in the fourth quarter valued at about $38,000. Hedge funds and other institutional investors own 67.78% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. Stifel Nicolaus raised their price objective on shares of Erasca from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Erasca in a research note on Tuesday, July 14th. Bank of America increased their target price on Erasca from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Tuesday, July 14th. Wolfe Research set a $16.00 price target on Erasca in a report on Thursday, June 4th. Finally, Mizuho reduced their price objective on Erasca from $28.00 to $26.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 12th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Erasca presently has an average rating of “Moderate Buy” and a consensus target price of $21.64.

Erasca Price Performance

NASDAQ:ERAS opened at $18.68 on Friday. The firm has a market cap of $5.81 billion, a PE ratio of -20.09 and a beta of 0.66. The firm has a 50 day simple moving average of $16.04 and a 200-day simple moving average of $14.36. Erasca, Inc. has a 1-year low of $1.33 and a 1-year high of $24.28.

Erasca (NASDAQ:ERAS) last announced its earnings results on Monday, May 11th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). As a group, sell-side analysts expect that Erasca, Inc. will post -0.54 earnings per share for the current fiscal year.

Key Headlines Impacting Erasca

Here are the key news stories impacting Erasca this week:

• Neutral Sentiment: Multiple law firms reminded investors that August 10, 2026 is the deadline to seek appointment as lead plaintiff in a federal securities class action covering purchases of Erasca securities from January 14, 2025, through April 26, 2026. Rosen Law Firm deadline notice
• Negative Sentiment: The lawsuits and investigations allege that Erasca and senior executives misled investors about ERAS-0015’s competitive advantages, safety profile, and intellectual-property protection. The allegations remain unproven, but litigation could create legal costs, management distraction, and potential financial liability. Hagens Berman investigation notice
• Negative Sentiment: Several notices reference a sequence involving patent-related concerns and reported patient-safety issues, including a patient death, which plaintiffs say damaged investor confidence and contributed to a substantial decline in Erasca’s stock during the class period. Levi and Korsinsky shareholder alert
• Negative Sentiment: One investor notice alleges that Erasca’s CEO and CFO certified misleading statements while the company raised approximately $258.8 million, potentially increasing scrutiny of executive disclosures and investor communications. SueWallSt shareholder notice

Erasca Profile

Erasca, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene?driven and immuno?oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.